#China #Suzhou #Gout Treatment #Innovent #IBI128

Innovent Biologics Initiates Phase 3 Clinical Trial for IBI128

Innovent Biologics, a leading biopharmaceutical company based in Suzhou and Hong Kong, has officially reported the first participant being dosed in its Phase 3 clinical study of IBI128, also known as Tigulixostat. This drug is gaining traction as a promising option for gout patients in China, following positive outcomes from earlier clinical trials.

Background on the Study

The Phase 3 study aims to compare the effectiveness of IBI128 against febuxostat, a common treatment for gout. Patients participating in this study will undergo a randomized, double-blind trial involving 600 Chinese patients who meet the 2015 ACR/EULAR diagnostic criteria for gout. Over the course of 24 weeks, patients will be assigned to receive either 100 mg of Tigulixostat or 40 mg of febuxostat, with the primary goal of achieving a serum uric acid (sUA) level of less than 360 μmol/L.

Previous Phase 2 trials indicated that Tigulixostat has a stronger urate-lowering effect than febuxostat, coupled with a favorable safety profile. Professor Zou Hejian from Huashan Hospital highlighted the ongoing challenges in gout treatment, pointing to safety concerns and insufficient efficacy as critical issues. The innovations represented by Tigulixostat offer hope to fill these gaps, especially in light of the rising prevalence of gout among the Chinese population, particularly among younger individuals.

Rising Gout Prevalence in China

Gout is rapidly becoming a prevalent chronic condition in China, demonstrating alarming statistics with an estimated 177 million people suffering from hyperuricemia and around 3.2% of the population diagnosed with gout. Shockingly, nearly 60% of patients fall between the ages of 18 and 35, and the average age of onset has significantly decreased to about 48 years, largely due to lifestyle factors such as high-purine diets and sedentary behavior.

The systemic impacts of gout extend beyond joint pain, as uncontrolled conditions can lead to irreversible organ damage, significantly impairing patients’ quality of life. Innovent's new treatment aims not only to address the symptoms but also tackle the underlying causes of this growing healthcare issue.

Innovation in Gout Treatment

Dr. Lei Qian, Chief RD Officer of Innovent, emphasized the urgent need for innovative therapeutic options for gout that can effectively lower uric acid levels while ensuring patient safety. IBI128's development represents Innovent's commitment to responding to the significant medical needs of gout patients. In addition to IBI128, Innovent Biologics is advancing other innovative programs, including IBI3011, aimed at controlling acute gout flares, and mazdutide, which is designed to treat obesity in patients with hyperuricemia.

Conclusion

The introduction of Tigulixostat into the market could represent a pivotal improvement in gout management for millions of affected patients in China. As this Phase 3 trial progresses, it aims to provide solid evidence that may transform clinical practice and patient outcomes. With the potential for both short-term relief and long-term health benefits, Innovent Biologics is poised to make a significant impact in the treatment landscape of gout and related conditions. More information about Innovent and its ongoing efforts in biopharmaceutical advancements can be found on their official website and associated social media channels.